NCT02928029 - Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions

Multiple Myeloma

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Sequential dose escalation in Intravenous (IV) injection

DRUG

Placebo

Matching placebo

DRUG

Bortezomib

Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose

DRUG

Dexamethasone

Dexamethasone is administered orally at 40 mg

Trial Locations (7)

Wake Forest Baptist Health, Winston-Salem

Hospital Universitario Virgen del Rocío, Seville

Pacific Oncology/Hematology Associates, Encinitas

Fred Hutchinson Cancer Research Center, Seattle

National Cancer Center, Goyang-si

Seoul National University Hospital, Seoul

Hospital Universitari Son Espases, Palma de Mallorca